Publikation: Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
In the context of the current COVID-19 pandemic, traditional, complex and lengthy methods of vaccine development and production would not have been able to ensure proper management of this global public health crisis. Hence, a number of technologies have been developed for obtaining a vaccine quickly and ensuring a large scale production, such as mRNA-based vaccine platforms. The use of mRNA is not a new concept in vaccine development but has leveraged on previous knowledge and technology. The great number of human resources and capital investements for mRNA vaccine development, along with the experience gained from previous studies on infectious diseases, allowed COVID-19 mRNA vaccines to be developed, conditionally approved and commercialy available in less than one year, thanks to decades of basic research. This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
CALINA, Daniela, Antonio F. HERNÁNDEZ, Thomas HARTUNG, Alexey M. EGOROV, Boris Nikolaevich IZOTOV, Taxiarchis Konstantinos NIKOLOUZAKIS, Aristidis TSATSAKIS, Panayiotis G. VLACHOYIANNOPOULOS, Anca Oana DOCEA, 2021. Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2. In: Life. MDPI. 2021, 11(9), 907. eISSN 2075-1729. Available under: doi: 10.3390/life11090907BibTex
@article{Calina2021-09Chall-55013, year={2021}, doi={10.3390/life11090907}, title={Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2}, number={9}, volume={11}, journal={Life}, author={Calina, Daniela and Hernández, Antonio F. and Hartung, Thomas and Egorov, Alexey M. and Izotov, Boris Nikolaevich and Nikolouzakis, Taxiarchis Konstantinos and Tsatsakis, Aristidis and Vlachoyiannopoulos, Panayiotis G. and Docea, Anca Oana}, note={Article Number: 907} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/55013"> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/55013/1/Calina_2-1vje3xdbqimqh7.pdf"/> <dc:creator>Hernández, Antonio F.</dc:creator> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/55013/1/Calina_2-1vje3xdbqimqh7.pdf"/> <dc:contributor>Izotov, Boris Nikolaevich</dc:contributor> <dc:contributor>Tsatsakis, Aristidis</dc:contributor> <dc:rights>Attribution 4.0 International</dc:rights> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-09-24T08:36:20Z</dcterms:available> <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/55013"/> <dcterms:abstract xml:lang="eng">In the context of the current COVID-19 pandemic, traditional, complex and lengthy methods of vaccine development and production would not have been able to ensure proper management of this global public health crisis. Hence, a number of technologies have been developed for obtaining a vaccine quickly and ensuring a large scale production, such as mRNA-based vaccine platforms. The use of mRNA is not a new concept in vaccine development but has leveraged on previous knowledge and technology. The great number of human resources and capital investements for mRNA vaccine development, along with the experience gained from previous studies on infectious diseases, allowed COVID-19 mRNA vaccines to be developed, conditionally approved and commercialy available in less than one year, thanks to decades of basic research. This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.</dcterms:abstract> <dc:creator>Izotov, Boris Nikolaevich</dc:creator> <dc:contributor>Docea, Anca Oana</dc:contributor> <dc:creator>Docea, Anca Oana</dc:creator> <dcterms:issued>2021-09</dcterms:issued> <dc:contributor>Egorov, Alexey M.</dc:contributor> <dc:creator>Egorov, Alexey M.</dc:creator> <dc:creator>Vlachoyiannopoulos, Panayiotis G.</dc:creator> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>Calina, Daniela</dc:contributor> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:contributor>Nikolouzakis, Taxiarchis Konstantinos</dc:contributor> <dc:creator>Hartung, Thomas</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-09-24T08:36:20Z</dc:date> <dc:language>eng</dc:language> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dc:creator>Calina, Daniela</dc:creator> <dc:contributor>Hartung, Thomas</dc:contributor> <dc:creator>Nikolouzakis, Taxiarchis Konstantinos</dc:creator> <dc:creator>Tsatsakis, Aristidis</dc:creator> <dc:contributor>Vlachoyiannopoulos, Panayiotis G.</dc:contributor> <dc:contributor>Hernández, Antonio F.</dc:contributor> <dcterms:title>Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2</dcterms:title> </rdf:Description> </rdf:RDF>